Year: 2026
Type: article
Abstract: Breast cancer is the most common malignancy among women in Korea and its incidence is rapidly increasing. Perioperative systemic treatment plays a critical role in achieving a cure for early-stage breast cancer. With the introduction of novel systemic agents, treatment outcomes have improved and perioperative strategies have become increasingly diverse. In addition to conventional anthracycline- and taxane-based chemotherapies, targeted therapies and/or immunotherapy have expanded the options to both neoadjuvant and adjuvant settings. Increasing numbers of (neo) novel adjuvant agents and post-neoadjuvant treatments have demonstrated survival benefits, supporting more individualized perioperative treatment approaches in patients with early breast cancer.
Source: Korean Journal of Medicine
Author: Hee Kyung Ahn
Institutions: Samsung Medical Center, Sungkyunkwan University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7148628228
FWCI:
Cites:
Cited by:
Related to: